Jan. 14 at 2:14 PM
$TRAW In my opinion this means very high likelihood of funding from BARDA for inclusion in national stockpile, given the results so far, the mutual relationship with HHS/TRAW leadership, and the emerging (yet currently under-appreciated and under-anticipated) need.
“This filing represents an important step towards formal consideration of TXM for influenza therapy and inclusion in the strategic national stockpile,” commented C. David Pauza, PhD, Chief Scientific Officer of Traws Pharma. “Coupled with our ongoing positive interactions with the U.S. Department of Health and Human Services (HHS) regarding the unique properties of TXM as a broad pan-influenza strain therapeutic, we remain optimistic about the potential inclusion of this agent in the nation's armamentarium against potential future disease outbreaks.”
